A number of national political figures are looking svelte these days.
asserted
number → look → figures
But it doesn’t do to rifle through public figures’ medicine cabinets.
asserted
it → do → cabinets
And only a few of them are saying much about the policy implications of the new class of miracle drugs that promise to reverse America’s obesity epidemic: GLP-1s.
asserted
that → say → epidemic
So I called up the only national figure who has both talked openly about his own treatment and taken concrete steps to expand coverage of the drugs to include weight loss: Illinois Gov. JB Pritzker.
asserted
who → call → loss
Pritzker was diagnosed with Type 2 diabetes in 2024 and began taking insulin.
asserted
Pritzker → diagnose → insulin
A doctor added a GLP-1 to his treatment protocol a few months later.
asserted
doctor → add → protocol
He’s since lost about 80 pounds and no longer takes insulin.
asserted
He → lose → insulin
He was feeling good when we spoke this week: He said he has more energy, he goes for walks, and he’s stepped off a lifelong “rollercoaster” of struggling with his weight.
“When I think about all the ill effects of obesity across the population, and the costs that come with it — and I’m talking about personal cost as well as financial cost — it feels to me like we may have stumbled onto something,” he marveled.
uncertain
he → feel → something
“As the price drops, we really ought to be offering this to everyone.”
asserted
we → drop → everyone
Illinois extended its coverage of the drugs — from covering them for just diabetes to also covering them for obesity — for state employees in 2024.
asserted
Illinois → extend → 2024
About 32,000 Illinois state employees and their family members are currently on the drugs, at a total cost of $149 million — a sum that Pritzker’s office says makes up 18% of the state’s prescription budget.
asserted
office → say → budget
For perspective, 41% goes to coverage of other brand-name specialty drugs taken by 6,500 employees.
asserted
% → go → employees
GLP-1s touch nerve centers of US healthcare politics, from populist fury at big insurers and pharmaceutical companies to worries about government spending and a growing awareness of the toll of chronic illness.
asserted
GLP-1s → touch → illness
But even as President Donald Trump pushed Eli Lilly and Novo Nordisk to lower prices and states, the 2028 campaign, which effectively begins after the midterms next week, will be the first presidential race during which the drugs will no longer be a novelty.
asserted
drugs → push → which
Pritzker hasn’t committed to running in 2028, and he’s not ready to make sweeping political claims or to push private companies to cover the drugs.
uncertain
he → commit → drugs
“If the cost savings bear themselves out, then I think you can campaign on it,” he said.
asserted
he → bear → it
2028 Math
The policy questions around GLP-1s are red-hot in state Medicaid and health plans — and in corporate boardrooms, where CEOs and human resources executives are balancing demand from employees with a hit to the bottom line.
asserted
CEOs → balance → line
Depending on expansion criteria, more than 40% of Americans under age 65 with private insurance could be clinically eligible for GLP-1s, a 2024 KFF study found.
uncertain
study → depend → GLP-1s
Those costs would add up: Americans taking a GLP-1 spend an average of $1,528 per year on their medication, including those with insurance coverage and without it.
asserted
Americans → add → it
Novo Nordisk, which makes Wegovy and Ozempic, advertises list prices ranging from $149 per month to $399 per month, depending on the dose.
asserted
which → make → dose
This year, seven states that expanded Medicaid coverage of GLP-1s for weight loss either dropped the benefit or added restrictions to limit eligibility.
asserted
that → expand → eligibility
(Illinois did not extend coverage to Medicaid enrollees.)
asserted
Illinois → extend → enrollees
Medicaid cuts passed in a 2025 tax bill set to take effect next year are expected to exacerbate states’ problems.
asserted
cuts → pass → problems
A key question is time: When does better health save healthcare money?
asserted
health → save → money
The median job tenure in the US is about four years, while the federal government evaluates health outcomes on a 10-year timetable.
asserted
government → evaluate → timetable
Pritzker said his state is carefully monitoring the savings GLP-1s bring and thinks they can at least defray some of the price tag.
asserted
they → say → tag
(It may help that “in state government, we have quite a lot of people who stay for a reasonably long period of time,” he said.)
uncertain
he → help → time
Others argue that narrow actuarial questions are a distraction from the larger political issue.
asserted
questions → argue → issue
“We borrow against our future for far worse reasons than the health of our citizens,” the CEO of the direct-to-consumer health care company Ro, Zachariah Reitano, told me.
asserted
CEO → borrow → me
The cost of the drugs there and in the private market limits their use, the philanthropist and former energy trader John Arnold notes.
asserted
philanthropist → limit → use
“Drugs don’t work if people can’t access them.
asserted
people → work → them
This class of drugs should be broadly available at a fair price,” he said.
asserted
he → say → price
About 32 million Americans take GLP-1s, a higher number than there are American Jews and Muslims combined.
asserted
Americans → take → number
About twice as many Americans take drugs as pay for artificial intelligence subscriptions.
asserted
Americans → take → subscriptions
Many are paying out-of-pocket sums comparable to expenses like gasoline.
asserted
Many → pay → gasoline
(I pay Eli Lilly $454 a month for 30 milligrams of Zepbound and some small needles, and would certainly be receptive, as a voter, to Pritzker’s or, say, JD Vance’s plan to save me a few bucks.
asserted
I → pay → bucks
Pritzker rolled them out quietly, and it seems possible that voters concerned about the growing cost of government (not to mention the small but influential minority of thin people) may have qualms about broader expansions.
uncertain
voters → roll → expansions
But it’s also obvious that anyone seeking the American presidency in 2028 will have to figure out a response to the challenging policy questions around the jabs.
asserted
anyone → ’ → jabs
People active in the space have some suggestions: Arnold called on Congress to block loopholes Novo Nordisk and Eli Lilly could use to delay competition from generic GLP-1s.
uncertain
Nordisk → have → GLP-1s
He also noted that the most obvious and effective solutions, like mandating public and private programs to cover GLP-1s for obesity, will be expensive.
asserted
programs → note → obesity
…and 4 more, not listed.
The Aporia
